Sharifi N - Search Results

1

3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.

Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. Evaul K, et al. Among authors: sharifi n. Endocrinology. 2010 Aug;151(8):3514-20. doi: 10.1210/en.2010-0138. Epub 2010 Jun 9. Endocrinology. 2010. PMID: 20534728

2

The genetics of castration-resistant prostate cancer: what can the germline tell us?

Sharifi N, Dahut WL, Figg WD. Sharifi N, et al. Clin Cancer Res. 2008 Aug 1;14(15):4691-3. doi: 10.1158/1078-0432.CCR-08-0453. Clin Cancer Res. 2008. PMID: 18676736 Free PMC article. Review.

3

Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.

Sharifi N. Sharifi N. Anticancer Agents Med Chem. 2009 Dec;9(10):1046-51. doi: 10.2174/187152009789735044. Anticancer Agents Med Chem. 2009. PMID: 19719456 Review.

4

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N. Sharifi N. Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Expert Opin Investig Drugs. 2010. PMID: 20524793 Review.

5

An update on androgen deprivation therapy for prostate cancer.

Sharifi N, Gulley JL, Dahut WL. Sharifi N, et al. Endocr Relat Cancer. 2010 Oct 29;17(4):R305-15. doi: 10.1677/ERC-10-0187. Print 2010 Dec. Endocr Relat Cancer. 2010. PMID: 20861285 Free PMC article. Review.

6

Survivin is not induced by novel taxanes.

Sharifi N, Qi J, Bane S, Sharma S, Li R, Robey R, Figg WD, Farrar WL, Kingston DG. Sharifi N, et al. Mol Pharm. 2010 Dec 6;7(6):2216-23. doi: 10.1021/mp100211k. Epub 2010 Oct 7. Mol Pharm. 2010. PMID: 20863081 Free PMC article.

7

"Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.

Sharifi N, McPhaul MJ, Auchus RJ. Sharifi N, et al. J Investig Med. 2010 Dec;58(8):938-44. doi: 10.231/JIM.0b013e3181ff6bb8. J Investig Med. 2010. PMID: 21030877 Free PMC article. Review.

8

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N. Chang KH, et al. Among authors: sharifi n. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13728-33. doi: 10.1073/pnas.1107898108. Epub 2011 Jul 27. Proc Natl Acad Sci U S A. 2011. PMID: 21795608 Free PMC article.

9

The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.

Sharifi N. Sharifi N. J Investig Med. 2012 Feb;60(2):504-7. doi: 10.2310/JIM.0b013e31823874a4. J Investig Med. 2012. PMID: 22064602 Free PMC article. Review.

10

SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.

Thomas R, Sharifi N. Thomas R, et al. Among authors: sharifi n. Mol Cancer Ther. 2012 Jan;11(1):87-97. doi: 10.1158/1535-7163.MCT-11-0540. Epub 2011 Dec 15. Mol Cancer Ther. 2012. PMID: 22172488 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

373 results

Search Page

Filters